Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma

Key Inclusion Criteria:

- A diagnosis of allergic asthma , uncontrolled on current medication.

- History of at least 1 asthma exacerbation during the last 1 year

- Forced Expiratory Volume in one second (FEV1) of ≥ 40% and ≤ 80% of the predicted
normal value; reversibility following administration of bronchodilator must also be
demonstrated (historical positive reversibility or bronchoprovocation result can be
used).

Key Exclusion Criteria:

- Baseline IgE levels or body weight outside the omalizumab dosing table.

- Use of tobacco products within the previous 6 months (Social occasional smokers may
be included).

- Recent asthma attack/exacerbation or asthma worsening/ respiratory infection.